MSK-TCR5 Cell Therapy for RAS G12D Solid Tumors
Part of Cancer clinical trials.
This study tests a new type of cell therapy called MSK-TCR5, designed to fight solid cancers (like pancreatic, lung, or colon cancer) that have a specific RAS G12D mutation. The therapy uses your own immune cells trained to recognize and attack cancer cells with this mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must have the RAS G12D genetic mutation and you must have a specific immune marker (HLA-A*11:01 allele)
- Your cancer must be advanced, unresectable (can't be surgically removed), or metastatic (spread), and you must have already tried at least one standard cancer treatment
- You must be at least 18 years old and in good enough health (ECOG performance status 0–1, roughly able to do light activity or self-care)
- Your blood counts and organ function must be adequate (healthy liver, kidney, and bone marrow)
- You cannot have had an organ transplant, untreated brain tumors, or active infections; you cannot be pregnant or nursing
- You cannot have HIV, hepatitis B, or hepatitis C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
This study tests a new treatment for people with advanced solid tumors that have a specific genetic change called KRAS G12V. The treatment is designed to help the immune system attack cancer cells with this mutation, and the study aims to see if it is safe and effective.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.